Contract
Manager Real World Evidence and Health Economics and Outcomes Research
18-Month Contract
Posted on 9/14/2026
AbbVie
10,001+ employees
Global biopharmaceutical company developing medicines
Compensation Overview
CA$112k - CA$162k/yr
Markham, ON, Canada
Hybrid
Travel within Canada and internationally is required about 10% of the time each.
Master's, PhD
 Biology & Biotech |
|---|
Get referred to AbbVie
See people who can refer or advise you
- An advanced Master's or PhD degree in biostatistics, epidemiology, health economics, outcomes research, public health, or a related field.
- At least 5 years of experience in real world evidence, health economics and outcomes research, or related roles within the pharmaceutical industry or consulting.
- Strong knowledge of the Canadian healthcare system, health technology assessment processes including CDA and INESSS, and data sources including electronic medical records, electronic health records, claims data, CIHI, and disease registries.
- Strong clinical acumen or the ability to acquire it quickly across different therapeutic areas.
- Effective communication, medical writing, technical, and presentation skills.
- Strategic thinking, analytical, and data interpretation skills to support value propositions addressing public and private payer needs.
- Strong cross-functional leadership and collaboration skills.
- Initiative and the ability to translate RWE and HEOR strategies into actionable, realistic plans.
- Prioritization and project management skills, including the ability to manage multiple projects across therapeutic areas and work under timeline pressure.
- High quality standards, rigor, and attention to detail.
- Understanding of public and private drug reimbursement landscapes, health technology assessment processes, and Canadian submission requirements.
- Understanding of pharmacoeconomic principles, guidelines, methodological developments, and the development of RWE and economic studies with internal and external experts.
- Experience participating in publication processes and RWE or data-generation projects.
- Advanced written and verbal English.
- Proficiency with Microsoft Office Suite, including Word, Excel, and PowerPoint, as well as Outlook.
- Experience working with payer-specific databases, clinical trial databases, and decision-modeling databases such as TreeAge.
- Availability to travel within Canada and internationally about 10% of the time each.
- A valid passport and driver's license.
- Serve as the primary HEOR and RWE subject matter expert and provide scientific and methodological expertise to market access managers and cross-functional teams.
- Develop and implement RWE and HEOR strategies to demonstrate value and support reimbursement, pricing strategies, clinical guidelines, and health policy decisions.
- Develop submission dossiers for CDA, INESSS, and private payers, including budgetary impact analyses and the development or adaptation of economic analyses.
- Liaise with the global market access organization to leverage the global value dossier, market access strategies, and payer tools.
- Collaborate with the global health economics organization to adapt economic analyses supporting reimbursement strategies and payer submissions in alignment with Canadian guidelines.
- Lead the planning and implementation of RWE and HEOR projects, including study design, data analysis, and dissemination of findings.
- Collaborate with Medical Affairs, Market Access, Government Affairs and Policy, Regulatory, and Commercial teams.
- Communicate RWE and HEOR study progress and results to investigators, brand teams, payers, policymakers, and other relevant audiences.
- Prepare abstracts and manuscripts of study results for publication or presentation.
- Liaise with patient and disease registries, consultants, contract research organizations, biostatisticians, epidemiologists, medical experts, and health economists on health economics and outcomes research projects.
- Build and maintain a network of Canadian institutions and organizations that collect relevant data for RWE and HEOR studies.
- Build trusted relationships to enable data access and data-quality improvement initiatives.
- Collaborate with clinical research on studies with economic and quality-of-life endpoints.
- Leverage AbbVie global RWE expertise and capacity to advance Canadian projects.
- Play an active role on brand teams to identify collaborative opportunities and deliver brand objectives.
- Monitor timelines and budget expenditures for RWE and HEOR studies.
- Stay current on Canadian healthcare trends, regulations, and data sources and champion innovation in RWE and HEOR methodologies.
- Ensure data quality, integrity, and compliance with legal, ethical, and regulatory standards.
- Experience in the pharmaceutical industry, preferably in Canada.
- Experience collaborating with government, academic institutions, data aggregators, or disease organizations.
- Previous experience dealing directly with payers.
- Advanced knowledge of French.
- Knowledge of Python, R, or SAS.
AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.
Company Size
10,001+
Company Stage
IPO
Headquarters
North Chicago, Illinois
Founded
1888
Get referred to AbbVie
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue reached $16.99 billion, up 10.2%, with EPS of $3.65.
- AbbVie raised 2026 guidance to $13.87-$14.07 after broad strength across immunology and neuroscience.
- Rinvoq and Skyrizi both grew above 23% operationally, showing durable post-Humira momentum.
What critics are saying
- Humira sales fell 36.1% in Q2 2026; biosimilars keep compressing cash flows.
- Imbruvica dropped 29.4% in Q2 2026, exposing oncology weakness and IRA pricing damage.
- Apogee dilutes adjusted EPS through 2027; if Skyrizi stalls, AbbVie loses its bridge.
What makes AbbVie unique
- Skyrizi and Rinvoq delivered $8.0 billion in Q2 2026, replacing Humira.
- AbbVie completed Apogee on September 3, 2026, adding long-acting immunology assets.
- Etentamig posted 74% response in Phase 3 multiple myeloma, broadening oncology optionality.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Flexible Work Hours
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 5%1 year growth
↑ 5%2 year growth
↑ 5%AbbVie has dramatically shifted its focus away from Humira, its once-flagship drug now facing biosimilar competition. On the company's July 2026 earnings call, Humira received just one sentence, noting global sales of $706 million, down 36.1% operationally but in line with expectations. This marks a stark change from previous quarters when management detailed the reasons behind Humira's decline, including biosimilar competition and molecule compression in the US market. AbbVie now emphasises growth drivers instead. Skyrizi generated $5.5 billion in Q2 2026, whilst Rinvoq exceeded $2.5 billion, both growing above 20% operationally. The company also acquired Apogee Therapeutics in September 2026. Despite the reduced attention, Humira still contributes approximately 4% of AbbVie's quarterly revenue of nearly $17 billion, though management no longer publicly projects its ultimate decline trajectory.
Israel Englander's Millennium Management more than doubled its stakes in AbbVie and Costco during the second quarter. AbbVie's revenue grew 10.2% year-over-year to $17 billion in Q2, driven by immunology drugs Skyrizi and Rinvoq. The company recently acquired Apogee Therapeutics for $10.9 billion in cash and is developing ABBV-295, a monthly weight-loss treatment. AbbVie is a Dividend King with over 50 consecutive years of payout increases. Costco's Q3 fiscal 2026 revenue rose 11.6% to $70.5 billion, with comparable sales up 9.8%. The company has raised dividends for 22 consecutive years. However, Costco shares are down 4% over the past year whilst trading at 40.8 times forward earnings, above the consumer staples average of 21.6 times. Both companies maintain strong fundamentals despite different market challenges.
AbbVie offers a smarter long-term dividend investment than Pfizer, despite Pfizer's higher 6.1% yield. AbbVie holds Dividend King status with 53 consecutive years of dividend increases and raised its payout by 5.5% this year to $1.73 per share. Over the past decade, AbbVie increased its dividend by more than 203% compared to Pfizer's 51%. AbbVie's revenue grew 138% during this period, whilst Pfizer's rose just 18%. AbbVie successfully navigated Humira's patent cliff through home-grown immunology drugs Skyrizi and Rinvoq. By 2025, these two drugs generated combined annual sales exceeding $25 billion, replacing Humira's peak revenue and pushing total company revenue to record highs. AbbVie's free-cash-flow dividend payout ratio stands at 65%, lower than Pfizer's 89%.
The Manufacturers Life Insurance Company acquired a $655.27 million stake in AbbVie Inc., according to its latest SEC Form 13F filing. Other institutional investors also increased their positions significantly during the same period. Norges Bank acquired a new $5.87 billion position, whilst Wellington Management Group boosted its holdings by 457.4%. AbbVie reported quarterly earnings per share of $3.65, exceeding forecasts, with revenue growth of 10.2% year over year. The company generated $16.99 billion in revenue last quarter, surpassing expectations. Equity analysts maintain a bullish outlook. Barclays, Wolfe Research, and BMO Capital Markets each set price targets of $300, with ratings of "overweight" or "outperform". The consensus rating is "Moderate Buy". Institutional investors currently hold 70.23% of AbbVie's shares, reflecting confidence in the biopharmaceutical company's strategy and performance.
AAPS PharmSci 360: CMC strategies, part 1. In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discussed how CMC review practices are evolving and what that means for manufacturing strategy. PharmTech spoke with Alfred Rumondor, PhD, CMC due diligence for external assets at AbbVie, and Swita Singh, PhD, Senior Director and Strategic CMC Leader at Bristol Myers Squibb, to learn more about their upcoming panel discussion, Navigating CMC Strategy in the Current Landscape, at, which is being held from October 25-28 in New Orleans. In part 1 of this 3-part interview, Rumondor and Singh discussed how chemistry, manufacturing, and controls (CMC) review practices are evolving and what that means for manufacturing strategy. Singh identified the most consequential shift as a move from informal, reviewer-dependent flexibility to formal, risk-based flexibility applied consistently across the product life cycle. She pointed to Operation TrailBlazer and updated phase 1 CMC guidance as examples, stating they are reducing required manufacturing data pre-investigational new drug application (IND). Singh also pointed out that cell and gene therapy programs no longer need 3 independent process performance qualification batches and can flex specifications for small-batch production. AI-driven tools and emerging credibility frameworks are reinforcing this trend by helping generate cleaner data packages for faster, more consistent regulatory decisions. Singh cautioned, however, that companies must build "risk justification muscle" rather than simply accepting flexibility at face value. Reduced requirements should be treated as deferral, not elimination, of data obligations; organizations need clear plans for when deferred data will be generated and which milestones trigger it. She emphasized investing early in comparability infrastructure, leveraging platform and prior-knowledge pathways, and engaging proactively with regulators. Rumondor addressed the pressure to compress development timelines. He argued the real question isn't whether compression is safe, but how to do it properly by working smarter rather than skipping steps. He cited premature form selection without adequate screening as a common shortcut that later may bring costly bridging and comparability studies, increasing both timeline and program risk. Compressed timelines are achievable, but only when teams rigorously plan the full development path upfront, according to Rumondor. About the speakers. Alfred Rumondor, PhD, is Director, Development Sciences Licensing and Acquisitions, at AbbVie. Dr. Swita Singh holds a Ph.D. in Pharmaceutical Sciences and brings over fifteen years of distinguished expertise in Chemistry, Manufacturing, and Controls (CMC) development across biologics, antibody drug conjugates, and small molecules, with a proven record of driving strategic initiatives, optimizing complex business processes, and leading cross-functional teams to achieve regulatory and operational excellence. Recognized for delivering innovative, end-to-end CMC strategies that guide programs from early clinical development through successful commercialization, she has cultivated talent and shaped organizational culture throughout her career, while her commitment to stakeholder communication and cross-functional collaboration has consistently advanced program objectives across the industry. Having built her expertise at Pfizer and Eli Lilly and Company, Dr. Singh currently serves at Bristol Myers Squibb (BMS), where she continues to lead CMC strategy in support of transformative therapeutic development.